Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Darden

Clinical Cardiac Electrophysiology Overland Park, KS Medical Doctor

NPI 1346653698 CMS profile 4221241

5100 W 110Th St, Overland Park, KS 66211

Open in the dashboard

General payments

$52,192

783 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$44,500 paid to institutions, not to them · program year 2025

Through program year 2025, Douglas Darden of Overland Park, KS is reported in the CMS Open Payments database as having received $52,192 across 783 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $44,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,815 175
2024 General $5,224 205
2023 General $11,914 169
2022 General $9,704 143
2021 General $1,901 41
2020 General $3,419 14
2019 General $6,215 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Darden
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Douglas Darden were reported at $13,815. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Douglas Darden Clinical Cardiac Electrophysiology median Middle half National median
2019 $6,215 $2,361 $585–$8,260 $163
2020 $3,419 $993 $247–$4,351 $114
2021 $1,901 $1,185 $326–$4,739 $132
2022 $9,704 $2,073 $554–$6,789 $149
2023 $11,914 $2,568 $759–$8,159 $160
2024 $5,224 $2,557 $703–$7,403 $164
2025 $13,815 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $13,682 182 payments
  2. Abbott Laboratories $11,095 281 payments
  3. Biosense Webster, Inc. $7,301 69 payments
  4. Biotronik Inc. $5,589 22 payments
  5. Medtronic Vascular, Inc. $4,734 26 payments
  6. Medical Device Business Services, Inc. $4,000 4 payments
  7. Boston Scientific Corporation $2,338 83 payments
  8. Philips Electronics North America Corporation $1,008 7 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $415 27 payments
  10. Pfizer Inc. $320 13 payments
  11. Other $1,710 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,737 723 payments
  2. Travel and Lodging $11,296 35 payments
  3. Consulting Fee $9,788 12 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,650 3 payments
  5. Grant $1,631 2 payments
  6. Education $1,091 7 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,000 1 payment
Products named General payments · program years 2019–2025
  1. Carto 3 $11,027 66 payments
  2. ENSITE PRECISION $2,652 33 payments
  3. AFFERA MAPPING SYSTEM $2,406 21 payments
  4. Micra $1,250 28 payments
  5. LINQ II $1,237 65 payments
  6. NA $1,155 5 payments
  7. ENSITE $1,075 37 payments
  8. US Und $929 2 payments
  9. Edora 8 DR-T $860 4 payments
  10. Acticor 7 VR-T DX $860 4 payments
  11. Other $15,649 468 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

704

Median for Cardiology: 2,533

Drug cost

$339,653

Median for Cardiology: $485,213

Branded share of claims

48.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 234 $252,634
Xarelto Rivaroxaban Brand 59 $56,630
Multaq Dronedarone Hcl Brand 19 $18,266
Flecainide Acetate Generic 88 $4,216
Dofetilide Generic 17 $4,052
Potassium Chloride Generic 11 $1,260
Metoprolol Succinate Generic 94 $988
Amiodarone Hcl Generic 31 $529
Sotalol Sotalol Hcl Brand 32 $509
Amlodipine Besylate Generic 35 $179

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$404,729

Medicare's payments for the services billed

Medicare patients

942

Average age 76

Services billed

4,296

460 women, 482 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 55%
Heart failure 50%
Arthritis 48%
Chronic kidney disease 39%
Diabetes 38%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $31
$31 — —
Tymlos
  • Radius Health, Inc. $27
$27 — —
Wegovy
  • Novo Nordisk Inc $24
$24 — —
Ozempic
  • Novo Nordisk Inc $22
$22 — —
Repatha
  • Amgen Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

783 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record